| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $270,176 ) |
| | 2024 | 2024 | ONCOSTING, LLC | 17 S CHESTER ST | BALTIMORE | MD | 21231-2008 | BALTIMORE CITY | USA | R44AI181290 | BCG overexpressing a small molecule STING agonist as a vaccine for TB | 000 | 1 | NIH | 6/20/2024 | $270,176 |
|
| Issue Date FY: 2023 ( Subtotal = $1,092,982 ) |
| | 2023 | 2023 | ONCOSTING LLC | 17 S CHESTER ST | BALTIMORE | MD | 21231-2008 | BALTIMORE CITY | USA | R44CA261506 | STING agonist-expressing BCG for bladder cancer | 003 | 3 | NIH | 8/28/2023 | $1,092,982 |
| | 2023 | 2022 | ONCOSTING LLC | 17 S CHESTER ST | BALTIMORE | MD | 21231-2008 | BALTIMORE CITY | USA | R44CA261506 | STING agonist-expressing BCG for bladder cancer | 000 | 2 | NIH | 11/2/2022 | $0 |
| | 2023 | 2022 | ONCOSTING, LLC | 17 S CHESTER ST | BALTIMORE | MD | 21231-2008 | BALTIMORE CITY | USA | R44CA261506 | STING agonist-expressing BCG for bladder cancer | 002 | 2 | NIH | 6/13/2023 | $68,123 |
| | 2023 | 2021 | ONCOSTING, LLC | 17 S CHESTER ST | BALTIMORE | MD | 21231-2008 | BALTIMORE CITY | USA | R44CA261506 | STING agonist-expressing BCG for bladder cancer | 001 | 1 | NIH | 6/13/2023 | -$68,123 |
|
| Issue Date FY: 2022 ( Subtotal = $907,018 ) |
| | 2022 | 2022 | ONCOSTING LLC | 17 S CHESTER ST | BALTIMORE | MD | 21231-2008 | BALTIMORE CITY | USA | R44CA261506 | STING agonist-expressing BCG for bladder cancer | 000 | 2 | NIH | 7/19/2022 | $907,018 |
|
| Issue Date FY: 2021 ( Subtotal = $244,436 ) |
| | 2021 | 2021 | ONCOSTING LLC | 17 S CHESTER ST | BALTIMORE | MD | 21231-2008 | BALTIMORE CITY | USA | R44CA261506 | STING agonist-expressing BCG for bladder cancer | 000 | 1 | NIH | 8/31/2021 | $244,436 |
|
|
